KR20190061158A - Anti-obesity composition comprising Suaeda japonica extract as effective component - Google Patents

Abstract

The present invention relates to an anti-obesity composition comprising a Suaeda japonica Makino extract as an active ingredient. The Suaeda japonica Makino extract of the present invention shows reduction effects of body weight, subcutaneous fat tissue and visceral adipose tissue of an obesity-induced animal model, and promotes energy metabolism by increased UCP-1 expression in the subcutaneous fat tissue and increasing body temperature when exposed to cold, thereby being usefully used as an anti-obesity dietary supplement or an obesity treatment agent.

Description

An anti-obesity composition comprising Sujeda japonica extract as an active ingredient,

The present invention relates to an anti-obesity composition containing a chile peony extract as an active ingredient.

Obesity is a state of excessive accumulation of adipose tissue in the body, usually a lot of weight in the case of obesity, but even if it is not obese, people with a lot of muscle can lose weight, so the body's excess fat tissue is defined as obesity do. Excessive intake of nutrients over a long period of time in relation to energy consumption induces obesity by energy imbalance, and in addition is associated with changes in hormones, genetic, mental health problems, and socioeconomic factors. As the global obesity population is increasing, the importance of obesity has become an important issue.

In order to prevent and improve obesity and to maintain a healthy weight, a balanced diet and regular exercise are needed to maintain the lifelong lifetime. In particular, fat cells can be reduced in size once they are made, but it is impossible to remove them naturally and it is left permanently in the human body, so it is important to prevent obesity from the beginning.

Methods for reducing calories consumed, increasing activity and exercise, and taking medications such as reducing fat absorption for the prevention, improvement, or treatment of obesity have been used.

Current treatments for obesity include fenfluramine, which inhibits the serotonin nervous system, ephedrine and caffeine through the noradrenergic nervous system, sibutramine, which simultaneously acts on the serotonin and noradrenergic nervous system, and olyrie, which inhibits the lipase produced by the pancreas, There are drugs such as start. However, pfuramilamine has been prohibited because of its side effects such as primary pulmonary hypertension and heart valve lesion, and other drugs have problems such as decreased blood pressure and lactic acidosis, and are used for patients with heart failure and renal disease There is a problem that can not be done. Therefore, there is a need to prevent, ameliorate, or develop a therapeutic substance for obesity with a low side effect.

Recently, a methodological study for obesity resolution has been the subject of beige adipogenesis of white adipose tissue which is a report of fat storage. As is well known in adipose tissue, white fat and brown fat are present. In general, white fat, which is composed mainly of abdominal obesity which is a cause of harmful obesity or metabolic syndrome, functions to store excess energy source in the form of fat and supply it to other organs as needed depending on the situation. Brown fat, which is present in some local parts of the body (between the scapulae, around the kidney, and behind the neck), and which contributes to maintaining the body temperature by inducing fever by using the fat energy source, plays the role of fat consumption. In other words, the activation of brown adipose tissue, which resolves excess fat energy, has emerged as a new way of addressing obesity. Recently, studies on brown adipose tissue have been actively conducted. Brown adipocytes specifically express UCP-1 (uncoupling protein) in the inner membrane of mitochondria, which in turn undergoes a related pairing reaction to generate heat instead of the bioenergy form ATP, contributing to the energy source consumption. It is clinically interpreted that people who are unable to tolerate the cold or feel cold, or abnormal hypothermia are physiological conditions that are not easy to overcome obesity. In other words, the tissue formation size of the brown fat is poor or the activation is low and the efficiency of the energy source consumption through the heat generation is low. In addition, the brown fat tissue has a large number of sympathetic nerves, so that the lipid degradation and the fatty acid oxidizing ability are more important.

Recently, it has been shown that the expression of UCP-1 is increased in white adipocytes, which are characterized by brown adipocytes, while white adipocyte traits are reduced by exercise or cold stimulation in the adipose tissue, Cell. These beef fat cells are known to be beneficial to obesity and metabolic diseases similar to brown fat cells found in rats. In addition, as brown fat cells found in humans are mostly known as beige fat cells, there is a growing interest in inducing the conversion or differentiation of white adipocytes, which are harmful to health, into beige fat cells which are relatively beneficial to health.

Thus, the regulation of UCP-1 protein activity and the production of beige (or brown) adipocytes have been the subject of major researches on obesity, and studies have been made on this subject, but it is not yet complete.

On the other hand, Chilgumcho is a representative vegetation of pearl tidal flats. It is submerged in seawater and is distributed in high soil salt concentration. The stem grows up to 10 ~ 50cm in height and does not spread much in the back part. The leaves are alternate flesh, short clubs or linear, pointed ends. With the stem, the entire body is reddish and the tidal flats are reddish. From August to September, there is a small flower in the upper part of the stem or branch. There is no flower stalk, it initially turns green but gradually turns purple. The calyx leaf is deeply divided into five branches, and there are five styles and two styles. Fugu is wrapped with calyx and contains one seed.

The turfgrass is strong against submergence, and it grows mainly in the low-tide area, which is submerged periodically in the tidal flat, and in the downstream area of the river. It is one of the pioneer plants in the early reclaimed land, and it grows in lowland areas, which are mainly in the vicinity of the sparrows or in the soil. However, time passes after reclamation, and most of the soil disappears as the soil dries.

On the other hand, Korean Patent No. 1261029 discloses a composition for preventing or improving diabetes mellitus including chile pepper. However, the composition for anti-obesity containing chile peach as an active ingredient has not been disclosed.

The present invention provides an anti-obesity composition comprising chile peony extract as an active ingredient. The composition is useful for reducing weight and fat tissue in an animal model in which obesity is induced, And increased the expression of UCP-1 in subcutaneous fat, thus completing the present invention.

In order to solve the above-mentioned problems, the present invention provides a health functional food composition for preventing or ameliorating obesity, comprising chile peel extract as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for preventing or treating obesity, comprising chile peel extract as an active ingredient.

The present invention relates to an anti-obesity composition comprising chile peel extract as an active ingredient. The chile peel extract of the present invention reduces body weight without any difference in feed intake in an animal model in which obesity is induced by a high fat diet, , Decreased the expression of FAS, leptin, PPAR-γ and AP2 in epididymal adipose tissue, significantly increased the expression of UCP-1 in subcutaneous adipose tissue, and increased body temperature by promoting metabolism .

FIG. 1 shows the results of examining the weight loss effect of chile peony root extract in an animal model in which obesity is induced by a high fat diet. NCD is a normal group to normal diet group, HFD-CTL is a group with high fat diet induced obese group, HFD-GK_245 and has a high fat diet Garcinia cambogia (Garcinia cambogia), and 245mg / kg / day orally a positive control group administered with, HFD-SJE_100 is a high fat diet, and a group orally administered S. japonica extract 100mg / kg / day, HFD- SJE_200 is, and the high fat diet S. japonica extract, 200mg / kg / day.
FIG. 2 shows the results of confirming the change in dietary intake (a) and the dietary efficiency (b) of the chili-headed herb extract in an animal model in which obesity is induced by a high fat diet. HFD-GK_245 is a high-fat diet, and is a positive control group administered orally at 245 mg / kg / day of Garcinia cambogia. HFD-GK_245 is a high- SJE_100 is a group of high-fat diets fed with 100 mg / kg / day of chili pepper extract and HFD-SJE_200 is a group of high-fat diets fed 200 mg / kg / day of chili pepper extract. +++ indicates a significant increase in the dietary efficiency of the high fat diet group compared to the normal dietary group, *, ** and *** indicate that the diet efficiency of the extract group was significantly lower than that of the high fat dietary group , +++ is p <0.001, * is p <0.05, ** is p <0.01 and *** is p <0.001.
FIG. 3 shows the result of examining the weight change of adipose tissue by the extract of chile peony root in an animal model in which obesity is induced by a high fat diet. HFD-GK_245 is a high-fat diet, and is a positive control group administered orally at 245 mg / kg / day of Garcinia cambogia. HFD-GK_245 is a high- SJE_100 is a group of high-fat diets fed with 100 mg / kg / day of chili pepper extract and HFD-SJE_200 is a group of high-fat diets fed 200 mg / kg / day of chili pepper extract. +++ indicates a significant increase in the weight of adipose tissue in the high-fat dietary group compared to the dietary group, and * and ** indicate that the weight of adipose tissue in the extract-treated group was significantly lower than that in the high fat dietary group , +++ is p <0.001, * is p <0.05, ** is p <0.01.
FIG. 4 shows the result of confirming the change in the area of adipocytes by the extract of chile peony root in an animal model in which obesity is induced by a high fat diet. HFD-GK_245 is a high-fat diet, and is a positive control group administered orally at 245 mg / kg / day of Garcinia cambogia. HFD-GK_245 is a high- SJE_100 is a group of high-fat diets fed with 100 mg / kg / day of chili pepper extract and HFD-SJE_200 is a group of high-fat diets fed 200 mg / kg / day of chili pepper extract. +++ indicates that the fat cell area of the high fat diet group was significantly higher than that of the normal diet group, *** indicates that the fat cell area of the extract group was significantly lower than that of the high fat diet group , +++ is p <0.001, *** is p <0.001.
FIG. 5 shows the result of examining the weight change of liver, kidney and spleen by the extract of chile pepper in an animal model in which obesity was induced by high fat diet. HFD-GK_245 is a high-fat diet, and is a positive control group administered orally at 245 mg / kg / day of Garcinia cambogia. HFD-GK_245 is a high- SJE_100 is a group of high-fat diets fed with 100 mg / kg / day of chili pepper extract and HFD-SJE_200 is a group of high-fat diets fed 200 mg / kg / day of chili pepper extract. +++ means that the body weight of the high fat diet group was significantly increased compared with the normal diet group, * indicates that the liver weight of the extract group was significantly lower than that of the high fat diet group, ++ is p < 0.001, * is p < 0.05.
FIG. 6 shows the result of checking the concentration of leptin (a) and adiponectin (b) in the blood by the extract of chile peony root in an animal model in which obesity is induced by a high fat diet. HFD-GK_245 is a high-fat diet, and is a positive control group administered orally at 245 mg / kg / day of Garcinia cambogia. HFD-GK_245 is a high- SJE_100 is a group of high-fat diets fed with 100 mg / kg / day of chili pepper extract and HFD-SJE_200 is a group of high-fat diets fed 200 mg / kg / day of chili pepper extract.
FIG. 7 shows the result of confirming the expression of gene expression in adipose tissue by the extract of chile peony root in an animal model in which obesity is induced by a high fat diet. HFD-GK_245 is a high-fat diet, and is a positive control group administered orally at 245 mg / kg / day of Garcinia cambogia. HFD-GK_245 is a high- SJE_100 is a group of high-fat diets fed with 100 mg / kg / day of chili pepper extract and HFD-SJE_200 is a group of high-fat diets fed 200 mg / kg / day of chili pepper extract.
FIG. 8 shows the results of UCP-1 expression in subcutaneous adipose tissue by the extract of chile peony root in an animal model in which obesity was induced by high fat diet. HFD-GK_245 is a high-fat diet, and is a positive control group administered orally at 245 mg / kg / day of Garcinia cambogia. HFD-GK_245 is a high- SJE_100 is a group of high-fat diets fed with 100 mg / kg / day of chili pepper extract and HFD-SJE_200 is a group of high-fat diets fed 200 mg / kg / day of chili pepper extract.
FIG. 9 shows the result of ascertaining the body temperature increase effect of the chile peel extract in an animal model in which obesity was induced by a high fat diet when exposed to low temperature. HFD-GK_245 is a high-fat diet, and is a positive control group administered orally at 245 mg / kg / day of Garcinia cambogia. HFD-GK_245 is a high- SJE_100 is a group of high-fat diets fed with 100 mg / kg / day of chili pepper extract and HFD-SJE_200 is a group of high-fat diets fed 200 mg / kg / day of chili pepper extract.

The present invention relates to a health functional food composition for preventing or ameliorating obesity, which contains chile peony extract as an active ingredient.

In one embodiment of the present invention, the extract of chile peel is extracted with water, C ₁ to C ₄ lower alcohol or a mixture thereof as a solvent. Preferably, the extract is extracted with ethanol as a solvent. Do not.

The chili pepper extract increases the expression of UCP-1 in subcutaneous fat and induces the formation of beige adipocytes from white fat. 'Beige fat cells' are cells that function similar to brown adipose cells in white adipose tissue, and play a role in consuming energy.

In the health functional food composition according to an embodiment of the present invention, the health functional food composition can inhibit an increase in body weight or accumulation of fat.

In the health functional food composition according to an embodiment of the present invention, the health functional food composition may contain fatty acid synthase (FAS), leptin, PPAR-gamma (peroxisome proliferators- activated receptor-γ) and AP2 (adipocyte protein 2), increase the expression of UCP-2 (uncoupling protein-2), and increase body temperature by promoting metabolism.

When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is, or may be used together with other food or food ingredients, and suitably used according to a conventional method. The amount of the active ingredient can be suitably used depending on its use purpose (prevention or improvement). Generally, the health functional food composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight based on the raw material, when the food or beverage is produced. However, in case of long-term ingestion for health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.

There is no particular limitation on the kind of the health functional food. Examples of the foods to which the health functional food composition can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, soups, Drinks, alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

In addition, the health functional food composition of the present invention can be produced as a food, particularly a functional food. The functional food of the present invention includes components that are ordinarily added in food production, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, when it is made of a drink, it may contain, in addition to the active ingredient, a natural carbohydrate or a flavoring agent as an additional ingredient. The natural carbohydrate may be selected from the group consisting of monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose etc.), oligosaccharides, polysaccharides (e.g., dextrin, cyclodextrin, , Xylitol, sorbitol, erythritol, etc.). The flavoring agent may be a natural flavoring agent (e.g., tau Martin, stevia extract, etc.) and a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).

In addition to the above-mentioned health functional food composition, various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, A carbonating agent used in beverages, and the like. Although the ratio of the above-mentioned ingredients is not critical, it is generally selected in the range of 0.01 to 0.1 part by weight based on 100 parts by weight of the health functional food composition of the present invention.

In addition, the present invention relates to a pharmaceutical composition for preventing or treating obesity, which contains chile peony extract as an active ingredient.

In one embodiment of the present invention, the pharmaceutical composition may be manufactured by, but not limited to, capsules, powders, granules, tablets or pills.

The pharmaceutical composition of the present invention may contain a pharmaceutically acceptable carrier in addition to the active ingredient. Such a carrier is usually used at the time of formulation, and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, Calcium carbonate, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and minerals Oils, and the like, but are not limited thereto. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc., in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences, 19th ed., 1995.

The appropriate dosage of the pharmaceutical composition according to the present invention may vary depending on such factors as the formulation method, the administration method, the patient's age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, .

The pharmaceutical composition of the present invention may be administered orally or parenterally. In the case of parenteral administration, the composition may be administered topically to the skin, intravenously, subcutaneously, intramuscularly, intraperitoneally, or transdermally.

The pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the inhibition and treatment of obesity.

The concentration of the active ingredient contained in the composition of the present invention can be determined in consideration of the purpose of treatment, the condition of the patient, the period of time required, and the like, and is not limited to a specific range of concentration.

The pharmaceutical composition of the present invention may be manufactured in a unit dosage form by formulating it using a pharmaceutically acceptable carrier or excipient according to a method which can be easily carried out by those having ordinary skill in the art to which the present invention belongs Into a capacity container. The formulations may be formulated into any one of the formulations selected from injectables, creams, patches, sprays, ointments, alerts, lotions, liniments, pastes and cataplasms, and may additionally contain dispersing or stabilizing agents have.

Hereinafter, the present invention will be described in more detail with reference to Preparation Examples and Examples. It is to be understood by those skilled in the art that these preparations and examples are merely intended to explain the present invention more specifically and that the scope of the present invention is not limited thereto.

Manufacturing example  One. Chili pepper  Preparation of extract

After drying, 15 kg of 70% (v / v) ethanol aqueous solution was added to 1 kg of crushed chilled meats, followed by reflux extraction at 85 ° C for 3 hours using a heating mantle (MS-DM609 / 20L). Then, the filtrate was concentrated under reduced pressure using a rotary vacuum evaporator (Rotavapor R-121, Buchi, Switzerland), and the concentrate was transferred to a freeze dryer (PF-10 / ALPHA 1-2 LD, Germany) And dried at a chamber temperature of -45 캜 and a vacuum pressure of 10 Torr or lower for 72 hours to obtain 112 g of a powder of chile peel extract. The obtained extracts of chile pepper extract were used as a sample for the experiment while being frozen and suspended in physiological saline for mouse administration.

Example  1. Experimental animal model design

For this experiment, 8-week-old male C57BL / 6J mice were distributed from Jackson laboratory (Bar Harbor, ME, USA) and maintained for 2 weeks under constant temperature (21 ± 2 ℃), humidity (50 ± 5% (Light on 07: 00 ~ 19: 00), and then randomly divided into groups of general diets, high fat diets, high fat diets + Garcinia cambogia extract, high fat diet + chili pepper extract 100 mg / kg Treated group, high fat diet + chili pepper extract 200mg / kg treated group, respectively.

High dietary diets (Rodent Diet D12492, Research Diet, New Brunswick, NL, USA) for inducing obesity consist of 60% fat, 20% protein and 20% carbohydrate, , NL, USA) consists of 11.5% fat, 20.8% protein and 67.7% carbohydrate.

The high fat diet and extracts were administered orally at the same time every day for 9 weeks in 10 week old mice, 245 mg / kg / day of Garcinia cambogia extract (GK), 100 mg / kg / ㎎ / ㎏ / day. Ordinary saline was administered orally to the dietary and high fat diet groups.

Body weight and dietary intake were measured and recorded at regular intervals every week, and the animals were sacrificed after fasting for 15 hours. Blood was collected by cardiac puncture method. Plasma was separated by centrifugation at 3000 rpm and 4 ° C for 15 minutes within 30 minutes after blood collection for blood biochemical examination. Separated plasma was stored at minus 70 ° C. Respectively. The organs and fat tissues were immediately extracted and weighed after blood sampling. The RNA samples were stored in RNA stable for one week, the remaining RNA was quenched with liquid nitrogen and stored at -70 ° C.

Example  2. Obesity-induced animal models in high-fat diets Chili pepper  Determine the effect of extract on body weight

Body weight, dietary intake, and diet efficiency were measured in the five groups of Example 1.

Body weight and dietary intake were measured at the same time every week, and the average daily dietary intake was calculated by dividing the measured intake by 7 days. The food efficiency ratio (FER) was calculated by the following equation (1).

[Formula 1]

FER = [total weight gain / total dietary intake] × 100

As a result, as shown in FIG. 1, it was confirmed that the body weight of the mice having a high fat diet increased sharply compared with that of the mice of the general formula, and in the group administered orally with chylomyrin extract (SJE) Was decreased.

Also, as shown in FIG. 2, there was no significant difference in the dietary intake between the groups, but the dietary efficiency was decreased.

Example  3. Obesity-induced animal models in high-fat diets Chili pepper  Identification of the effects of extracts on adipose tissue

The adipose tissues extracted from Example 1 are classified into abdominal subcutaneous fat, epididymal adipose tissue, kidney adipose tissue and intestine adipose tissue depending on the position. And weights were measured.

As a result, as shown in FIG. 3, the weight of adipose tissue was increased by the high fat diet, and the intestinal and subcutaneous adipose tissues were decreased compared with the high fat dietary group by the addition of chile pepper extract (SJE) The reduction effect of the organization was the largest.

The white adipose tissue surrounding the epididymis was cut to a thickness of 6 μm and then stained with H & E or Oil-red-O. The white adipose tissue was stained with an optical microscope (Olympus BX51, Olympus Optical Co., The mean value of 20 adipocytes was measured using an image analyzer (Image-Pro Plus 5.0, Media Cybernetics, Silver Spring, MD, USA).

As a result, as shown in FIG. 4, the area of the fat cells increased by the high fat diet decreased by the administration of the chili pepper extract.

Meanwhile, as shown in FIG. 5, the weight of each organs extracted in Example 1 was measured. As a result, the weight of the liver was slightly decreased during the administration of the chilcorrhizae extract, but the weight of the kidney and spleen did not differ .

Example  4. Obesity-induced animal models in high-fat diets Chili pepper  Changes of blood adipokines by extracts

The content of leptin and adiponectin in blood from the blood collected in Example 1 was analyzed using an ELISA kit (R & D Systems, Minneapolis, MN, USA).

As a result, the concentration of leptin in the blood increased by the high-fat diets decreased when the chili-chum extract was administered (Fig. 6 (a)), but the concentration of adiponectin did not change by the high-fat diet, ). However, the concentration of the extract was not changed by the extract of chile peach (Fig. 6 (b)).

Example  5. High Fat By diet  In obese-induced animal models Chili pepper  Changes in gene expression in adipose tissue surrounding adipose tissue by extracts

The effect of the chilbeechus extract on gene expression was examined in a mouse in which obesity was induced by a high fat diet using the adipose tissue surrounding adipose tissue extracted in Example 1.

After the homogenization of the adipose tissue surrounding the epididymis, total RNA was extracted using TRI reagent (Sigma, St. Louis, Mo., USA) and DNase I (Life Technologies, Grand Island, NY, USA) (chromosomal DNA) was removed.

The extracted RNA was amplified using the SYBR Green one-step qRT-PCR kit (Invitrogen, Carlsbad, Calif.) And Light Cycler (Roche, Indianapolis, Ind.) According to Boden (Diabetes, 2005, 54: 3458-3465) And the amount of expression was confirmed.

As a result, as shown in FIG. 7, the expression of AP2, FAS, leptin, SREBP1c and PPAR-γ was increased by high fat diet, but decreased by the administration of chile pepper extract. The expression of UCP-2 was decreased by high fat diet and slightly increased by the addition of chile pepper extract. UCP is a protein located in the mitochondrial inner membrane that has three types of UCP-1, 2 and 3, and it consumes energy by making hydrogen ions generated in the process of oxidative phosphorylation to be used for producing heat instead of synthesizing ATP , It is known to increase metabolic rate and fat removal effect.

Example  6. Obesity-induced animal models in high-fat diets Chili pepper  Extract-induced subcutaneous fat UCP -1 expression change

UCP-1 gene expression was analyzed by using the subcutaneous adipose tissue extracted from Example 1 in a high fat diet-induced obese mice.

RNA extraction and polymerase chain reaction (PCR) were performed in the same manner as in Example 5.

As a result, as shown in FIG. 8, UCP-1 expression in subcutaneous adipose tissue was decreased by the high fat diet, but UCP-1 expression was significantly enhanced in the group administered with the chili pepper extract with the high fat diet . UCP-1 is a brown fat-specific marker that plays a role in energy consumption. The increase in UCP-1 expression in subcutaneous fat, white adipose tissue, indicates that beefy fat cells, which play a role of brown fat in white fat, are formed.

Example  7. Obesity-induced animal models in high-fat diets Chili pepper  Effect of body temperature increase by extract

Changes in body temperature according to the time of extract administration (30, 60, 90, 120, 180 minutes) in a cold chamber maintained at 10 ° C at the end of 8 weeks of high fat diet and extract administration in the animal model of Example 1 Were measured by rectal temperature measurement. The temperature was measured using a Thermalert model TH-8 temperature monitor, with the probe placed in a 2.5 cm deep rectum and within 30 seconds per flock.

As a result, as shown in FIG. 9, there was no difference in body temperature after 30 minutes of administration of the extract, but the body temperature of the chickpea extract-treated group was higher than that of the normal diet group and the high fat diet group after 60 minutes and the chickpea extract- The increase of body temperature was better when exposed to cold than the 200 mg / The increase in temperature elevation effect when exposed to low temperature means that energy metabolism occurs actively, and it is judged that the antiobesity effect is caused by the increased energy metabolism.

Claims (5)

A health functional food composition for prevention or amelioration of obesity containing an extract of chile peel as an active ingredient. The health functional food composition according to claim 1, wherein the solvent of the extract of chile peel is water, a C ₁ -C ₄ lower alcohol or a mixture thereof. 3. The method according to claim 1, wherein the extract of Chilchimon pea extract induces the formation of beige adipocytes by increasing the expression of UCP-1 in subcutaneous fat. Food composition. A pharmaceutical composition for the prevention or treatment of obesity comprising an extract of chile peony root as an active ingredient. The pharmaceutical composition for preventing or treating obesity according to claim 4, wherein the pharmaceutical composition is prepared from any one selected from the group consisting of capsules, powders, granules, tablets and pills.

Images